TY - JOUR
T1 - Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes
AU - Ikeda, Masanori
AU - Sugiyama, Kazuo
AU - Tanaka, Torahiko
AU - Tanaka, Katsuaki
AU - Sekihara, Hisahiko
AU - Shimotohno, Kunitada
AU - Kato, Nobuyuki
N1 - Funding Information:
We are grateful to T. Mizutani for helpful suggestion. This work was supported by Grants-in-Aid for Cancer Research and for the Second-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare, and Grants-in-Aid for Sci-enti®c Research from the Ministry of Education, Science and Culture of Japan. M.I. is a recipient of Research Resident Fellowship from the Foundation for Promotion of Cancer Research, Japan.
PY - 1998/4/17
Y1 - 1998/4/17
N2 - We found that bovine lactoferrin (bLF), a milk protein belonging to the iron transporter family, effectively prevented hepatitis C virus (HCV) infection in cultured human hepatocytes (PH5CH8), a cell line susceptible to HCV infection and supportive of HCV replication. Because preincubation of HCV with bLF was required to prevent the infection of HCV to the cells, and preincubation of bLF with the cells showed no inhibitory effect on HCV infection, we demonstrated that the anti-HCV activity of bLF was due to the interaction of bLF with HCV, but not due to the interaction of bLF with the cells. We further found that human lactoferrin also had anti-HCV activity, but bovine transferrin, the other member of the iron transporter family, did not have anti-HCV activity. Our findings suggest that lactoferrin is one of candidates for an anti-HCV reagent that will be well-tolerated and effective in the treatment of patients with chronic hepatitis.
AB - We found that bovine lactoferrin (bLF), a milk protein belonging to the iron transporter family, effectively prevented hepatitis C virus (HCV) infection in cultured human hepatocytes (PH5CH8), a cell line susceptible to HCV infection and supportive of HCV replication. Because preincubation of HCV with bLF was required to prevent the infection of HCV to the cells, and preincubation of bLF with the cells showed no inhibitory effect on HCV infection, we demonstrated that the anti-HCV activity of bLF was due to the interaction of bLF with HCV, but not due to the interaction of bLF with the cells. We further found that human lactoferrin also had anti-HCV activity, but bovine transferrin, the other member of the iron transporter family, did not have anti-HCV activity. Our findings suggest that lactoferrin is one of candidates for an anti-HCV reagent that will be well-tolerated and effective in the treatment of patients with chronic hepatitis.
UR - http://www.scopus.com/inward/record.url?scp=0032540093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032540093&partnerID=8YFLogxK
U2 - 10.1006/bbrc.1998.8481
DO - 10.1006/bbrc.1998.8481
M3 - Article
C2 - 9571193
AN - SCOPUS:0032540093
SN - 0006-291X
VL - 245
SP - 549
EP - 553
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -
